NovoThirteen, also known by its active ingredient Catridecacog, is a specialized medication designed for the treatment of congenital Factor XIII A-subunit deficiency. This rare but critical condition affects the blood's ability to clot properly, leading to a risk of severe bleeding. NovoThirteen works by replacing the missing or malfunctioning Factor XIII, a protein essential for normal blood clotting, thereby helping to prevent bleeding episodes. It is typically administered through injection and is used both for routine prophylaxis to prevent bleeding and for management of bleeding episodes in individuals diagnosed with this specific form of clotting disorder. As a targeted therapy, NovoThirteen represents a significant advancement in the treatment of congenital Factor XIII A-subunit deficiency, offering hope for improved quality of life for those affected by this rare condition.